New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.
North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18. The new test was developed with the help of PerkinElmer and is now in use in Ontario, Canada.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a squamous cell carcinoma cancer case study, Dr. Fox uses the instrumentation to help develop predictive biomarkers.
No parents ever want to hear that their child has Duchenne Muscular Dystrophy (DMD). The most common fatal X chromosome genetic disorder diagnosed in childhood, DMD affects 1 in every 3,500 boys born each year.
The Philippines is celebrating the 20th anniversary of newborn screening by announcing a further expansion of the program and its goals.
Sub-Saharan Africa has the highest percentage of births with sickle cell disease. Dr. Russell E. Ware and PerkinElmer are collaborating to train African medical technicians to conduct SCD screening on their own.